Nikhil Prasad Fact checked by:Thailand Medical News Team Aug 12, 2026 49 minutes ago
The neurological consequences of COVID-19 continue to attract intense scientific attention as researchers investigate why some patients develop persistent brain fog, fatigue, anxiety, sleep disturbances, autonomic problems, and other neurological or neuropsychiatric symptoms. One emerging area of interest involves oxytocin, a neuropeptide whose functions extend far beyond social bonding.
Emerging research is examining whether COVID-19-associated inflammation and neuroendocrine disruption can
interfere with the brain’s oxytocin signaling pathways
Researchers have proposed that SARS-CoV-2 infection and the inflammatory responses it triggers could disrupt oxytocin signaling, particularly through effects involving the hypothalamus, neuroinflammation, systemic cytokines, and the gut-brain axis. However, direct evidence demonstrating sustained depletion of brain oxytocin in COVID-19 patients remains limited, making this an important field for further investigation.
Oxytocin Is More Than a Social Hormone
Oxytocin is synthesized predominantly by neurons within the paraventricular and supraoptic nuclei of the hypothalamus. Although widely associated with childbirth, lactation, social attachment, empathy, and emotional behavior, oxytocin also participates in immune regulation, cardiovascular function, autonomic control, stress responses, and inflammatory signaling.
Importantly, experimental research indicates that oxytocin can exert anti-inflammatory and neuroprotective effects. Consequently, disruption of normal oxytocinergic activity during or after SARS-CoV-2 infection could potentially contribute to some neurological manifestations associated with COVID-19.
Neuroinflammation Could Disrupt Hypothalamic Signaling
One proposed mechanism involves inflammation affecting hypothalamic and other central nervous system pathways. SARS-CoV-2 can generate profound systemic immune activation, while neurological complications may occur through vascular injury, immune-mediated mechanisms, blood-brain barrier dysfunction, and, in some circumstances, viral involvement of nervous-system tissues.
Inflammatory mediators including interleukin-6 and tumor necrosis factor-alpha can alter neuronal activity and neuroendocrine signaling. If inflammation interferes with hypothalamic neurons responsible for producing and releasing oxytocin, normal oxytocin signaling could theoretically decline.
This Thailand
Medical News report highlights that the hypothesis is especially relevant to long COVID because persistent neuroinflammatory or immune abnormalities could potentially maintain neuroendocrine disturbances after the acute infection has resolved.
The Gut-Brain Axis Adds Another Dimension
COVID-19 frequently affects the gastrointestinal system, and SARS-CoV-2-associated changes in intestinal permeability, inflammation, and microbial composition have generated considerable interest.
The gut microbiome communicates with the brain through neural, immune, metabolic, and endocrine pathways. Certain microorganisms, in
cluding Limosilactobacillus reuteri, have been associated experimentally with oxytocin-related biological responses.
Researchers have therefore proposed that COVID-19-associated dysbiosis could indirectly alter oxytocin signaling. Damage to intestinal barrier integrity may permit microbial products to enter circulation, promoting systemic inflammation that could subsequently influence hypothalamic function.
Links to Long-COVID Symptoms
Reduced or dysfunctional oxytocin signaling could theoretically have wide-ranging consequences. Oxytocin normally interacts with pathways controlling inflammation, stress, cardiovascular activity, social behavior, and autonomic balance.
Disturbances could therefore contribute to anxiety, altered emotional processing, sleep abnormalities, social withdrawal, cardiovascular dysfunction, or autonomic symptoms. Reduced anti-inflammatory oxytocin activity might also permit inflammatory pathways, including NF-κB-associated signaling, to remain more active.
These mechanisms remain hypotheses rather than proof that oxytocin deficiency causes long COVID. Measurements of peripheral oxytocin also cannot automatically be interpreted as representing concentrations inside specific brain regions.
Could Oxytocin Become a Treatment?
The possibility has nevertheless generated therapeutic interest. Researchers have discussed oxytocin as a potential adjunct because of its anti-inflammatory, immunomodulatory, cardiovascular, and neuroprotective properties.
Intranasal administration is particularly interesting because it is being investigated as a means of influencing central oxytocin pathways. Proposed benefits include moderating excessive inflammation, supporting autonomic regulation, and potentially improving selected neuropsychiatric symptoms.
However, oxytocin should not currently be regarded as an established treatment for acute COVID-19 or long COVID. Controlled clinical trials are required to determine appropriate dosing, treatment duration, safety, patient selection, and whether restoring oxytocin signaling actually produces meaningful clinical improvements.
Overall, available research raises an intriguing possibility that SARS-CoV-2-associated inflammation, hypothalamic dysfunction, intestinal dysbiosis, and disrupted neuroendocrine communication could alter oxytocin pathways and contribute to persistent symptoms. Larger human studies measuring central and peripheral oxytocin alongside neurological, immune, gastrointestinal, and autonomic biomarkers will be essential before researchers can establish causality or recommend oxytocin-based therapies.
References:
https://www.pasteur.fr/en/home/press-area/press-documents/long-covid-sars-cov-2-persists-brainstem-long-term-and-deregulates-neuronal-activity
https://www.sciencedirect.com/science/article/pii/S0306987720332515
https://www.preprints.org/manuscript/202411.2109
https://www.sciencedirect.com/science/article/pii/S0024320521001156
https://pmc.ncbi.nlm.nih.gov/articles/PMC8650193/
https://www.ovid.com/jnls/md-journal/fulltext/10.1097/md.0000000000046093~exploring-sars-cov-2-impact-on-blood-brain-barrier-and-its
https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.799521/full
https://pmc.ncbi.nlm.nih.gov/articles/PMC8592845/
https://academic.oup.com/brain/article/149/6/2151/8530637?login=false
Read Also:
https://www.thailandmedical.news/articles/coronavirus
https://www.thailandmedical.news/articles/long-covid
Share
Tweet
Share
